Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk
Source
Cells - ISSN 2073-4409-12:15 (2023) p. 1-28
Progression-free survival and safety at 3.5 years of follow-up : results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Source
European journal of cancer - ISSN 0959-8049-189 (2023) p. 1-13
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Source
Gynecologic oncology - ISSN 0090-8258-170 (2023) p. 300-308
Extensive CArdioVAscular characterization and follow-up of patients receiving immune checkpoint inhibitors : a prospective multicenter study
Source
Pharmaceuticals - ISSN 1424-8247-16:4 (2023) p. 1-14
First evidence of activity of enfortumab vedotin on brain metastases in urothelial cancer patients
Source
Pharmaceuticals - ISSN 1424-8247-16:3 (2023) p. 1-8